Lacy B.E., Mearin F., Chang L., Chey W.D., Lembo A.J., Simren M. Spiller R. Bowel Disorders. Gastroenterology. 2016;150(6)1393–1407.E5. https://doi.org/10.1053/j.gastro.2016.02.031..
DOI: 10.1053/j.gastro.2016.02.031
Canavan C., West J., Card T. Review article: the economic impact of the irritable bowel syndrome. Aliment Pharmacol Ther. 2014;40(9):1023–1034. https://doi.org/10.1111/apt.12938..
DOI: 10.1111/apt.12938
Lovell R.M., Ford A.C. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012;10(7):712–721.e4. https://doi.org/10.1016/j.cgh.2012.02.029..
DOI: 10.1016/j.cgh.2012.02.029
Singh P., Staller K., Barshop K., Dai E., Newman J., Yoon S. et al. Patients with irritable bowel syndrome-diarrhea have lower disease-specific quality of life than irritable bowel syndrome-constipation. World J Gastroenterol. 2015;21(26):8103–8109. https://doi.org/10.3748/wjg.v21.i26.8103..
DOI: 10.3748/wjg.v21.i26.8103
Fond G., Loundou A., Hamdani N., Boukouaci W., Dargel A., Oliveira J. et al. Anxiety and depression comorbidities in irritable bowel syndrome (IBS): a systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci. 2014;264(8):651–660. https://doi.org/10.1007/s00406-014-0502-z..
DOI: 10.1007/s00406-014-0502-z
Casiday R.E., Hungin A.P., Cornford C.S., de Wit N.J., Blell M.T. GPs’ explanatory models for irritable bowel syndrome: a mismatch with patient models? Fam Pract. 2009;26(1):34–39. https://doi.org/10.1093/fampra/cmn088..
DOI: 10.1093/fampra/cmn088
Drossman D.A. Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features and Rome IV. Gastroenterology. 2016;150(6):1262–1279.E2. https://doi.org/10.1053/j.gastro.2016.02.032..
DOI: 10.1053/j.gastro.2016.02.032
Simrén M., Barbara G., Flint H.J., Spiegel B.M., Spiller R.C., Vanner S. et al. Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut. 2013;62(1):159–176. https://doi.org/10.1136/gutjnl-2012-302167..
DOI: 10.1136/gutjnl-2012-302167
Rajilić-Stojanović M., Jonkers D.M., Salonen A., Hanevik K., Raes J., Jalanka J. et al. Intestinal microbiota and diet in IBS: causes, consequences, or epiphenomena? Am J Gastroenterol. 2015;110(2):278–287. https://doi.org/10.1038/ajg.2014.427..
DOI: 10.1038/ajg.2014.427
Pittayanon R., Lau J.T., Yuan Y., Leontiadis G.I., Tse F., Surette M., Moayyedi P. Gut Microbiota in Patients With Irritable Bowel Syndrome-A Systematic Review. Gastroenterology. 2019;157(1):97–108. https://doi.org/10.1053/j.gastro.2019.03.049..
DOI: 10.1053/j.gastro.2019.03.049
Hugerth L.W., Andreasson A., Talley N.J., Forsberg A.M., Kjellström L., Schmidt P.T. et al. No distinct microbiome signature of irritable bowel syndrome found in a Swedish random population. Gut. 2020;69(6):1076–1084. https://doi.org/10.1136/gutjnl-2019-318717..
DOI: 10.1136/gutjnl-2019-318717
Adak A., Khan M.R. An insight into gut microbiota and its functionalities. Cell Mol Life Sci. 2019;76(3):473–493. https://doi.org/10.1007/s00018-018-2943-4..
DOI: 10.1007/s00018-018-2943-4
Sommer F., Anderson J.M., Bharti R., Raes J., Rosenstiel P. The resilience of the intestinal microbiota influences health and disease. Nat Rev Microbiol. 2017;15(10):630–638. https://doi.org/10.1038/nrmicro.2017.58..
DOI: 10.1038/nrmicro.2017.58
Baj A., Moro E., Bistoletti M., Orlandi V., Crema F., Giaroni C. Glutamatergic Signaling Along The Microbiota-Gut-Brain Axis. Int J Mol Sci. 2019;20(6):1482. https://doi.org/10.3390/ijms20061482..
DOI: 10.3390/ijms20061482
Luo M., Zhuang X., Tian Z., Xiong L. Alterations in short-chain fatty acids and serotonin in irritable bowel syndrome: a systematic review and meta-analysis. BMC Gastroenterol. 2021;21(1):14. https://doi.org/10.1186/s12876-020-01577-5..
DOI: 10.1186/s12876-020-01577-5
Cremon C., Carini G., Wang B., Vasina V., Cogliandro R.F., De Giorgio R. et al. Intestinal serotonin release, sensory neuron activation, and abdominal pain in irritable bowel syndrome. Am J Gastroenterol. 2011;106(7):1290–1298. https://doi.org/10.1038/ajg.2011.86..
DOI: 10.1038/ajg.2011.86
Aggarwal S., Ahuja V., Paul J. Dysregulation of GABAergic Signalling Contributes in the Pathogenesis of Diarrhea-predominant Irritable Bowel Syndrome. J Neurogastroenterol Motil. 2018;24(3):422–430. https://doi.org/10.5056/jnm17100..
DOI: 10.5056/jnm17100
Farzaei M.H., Bahramsoltani R., Abdollahi M., Rahimi R. The Role of Visceral Hypersensitivity in Irritable Bowel Syndrome: Pharmacological Targets and Novel Treatments. J Neurogastroenterol Motil. 2016;22(4):558–574. https://doi.org/10.5056/jnm16001..
DOI: 10.5056/jnm16001
Gros M., Gros B., Mesonero J.E., Latorre E. Neurotransmitter Dysfunction in Irritable Bowel Syndrome: Emerging Approaches for Management. J Clin Med. 2021;10(15):3429. https://doi.org/10.3390/jcm10153429..
DOI: 10.3390/jcm10153429
Annaházi A., Róka R., Rosztóczy A., Wittmann T. Role of antispasmodics in the treatment of irritable bowel syndrome. World J Gastroenterol. 2014;20(20):6031–6043. https://doi.org/10.3748/wjg.v20.i20.6031..
DOI: 10.3748/wjg.v20.i20.6031
Ruepert L., Quartero A.O., de Wit N.J., van der Heijden G.J., Rubin G., Muris J.W. Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev. 2011;(8):CD003460. https://doi.org/10.1002/14651858.CD003460.pub3..
DOI: 10.1002/14651858.CD003460.pub3
Ивашкин В.Т., Маев И.В., Шелыгин Ю.А., Баранская Е.К., Белоус С.С., Белоусова Е.А. и др. Диагностика и лечение синдрома раздраженного кишечника (клинические рекомендации Российской гастроэнтерологической ассоциации и Ассоциации колопроктологов России). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2021;31(5):74–95. https://doi.org/10.22416/1382-4376-2021-31-5-74-95..
DOI: 10.22416/1382-4376-2021-31-5-74-95
Poynard T., Regimbeau C., Benhamou Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 2001;15(3):355–261. https://doi.org/10.1046/j.1365-2036.2001.00937.x..
DOI: 10.1046/j.1365-2036.2001.00937.x
Christen M.M.O., Tassignon J.P. Pinaverium bromide: A calcium channel blocker acting selectively on the gastrointestinal tract. Drug Dev Res. 1989;(18):101–112. https://doi.org/10.1002/ddr.430180202..
DOI: 10.1002/ddr.430180202
López-Alvarenga J.C., Sobrino-Cossío S., Remes-Troche J.M., Chiu-Ugalde J., Vargas-Romero J.A., Schmulson M. Polar vectors as a method for evaluating the effectiveness of irritable bowel syndrome treatments: an analysis with pinaverium bromide 100mg plus simethicone 300mg po bid. Rev Gastroenterol Mex. 2013;78(1):21–27. https://doi.org/10.1016/j.rgmx.2012.10.003..
DOI: 10.1016/j.rgmx.2012.10.003
Salvioli B. Trimebutine: a state-of-the-art review. Minerva Gastroenterol Dietol. 2019;65(3):229–238. https://doi.org/10.23736/S1121-421X.19.02567-4..
DOI: 10.23736/S1121-421X.19.02567-4
Martínez-Vázquez M.A., Vázquez-Elizondo G., González-González J.A., Gutiérrez-Udave R., Maldonado-Garza H.J., Bosques-Padilla F.J. Effect of antispasmodic agents, alone or in combination, in the treatment of Irritable Bowel Syndrome: systematic review and meta-analysis. Rev Gastroenterol Mex. 2012;77(2):82–90. https://doi.org/10.1016/j.rgmx.2012.04.002..
DOI: 10.1016/j.rgmx.2012.04.002
Den Hertog A., Van den Akker J. Modification of alpha 1-receptor-operated channels by mebeverine in smooth muscle cells of guinea-pig taenia caeci. Eur J Pharmacol. 1987;138(3):367–374. https://doi.org/10.1016/0014-2999(87)90475-4..
DOI: 10.1016/0014-2999(87)90475-4
Greenslade F.C., Scott C.K., Newquist K.L., Krider K.M., Chasin M. Heterogeneity of biochemical actions among vasodilators. J Pharm Sci. 1982;71(1):94–100. https://doi.org/10.1002/jps.2600710123..
DOI: 10.1002/jps.2600710123
Rosenzweig O., Lavy E., Gati I., Kohen R., Friedman M. Development and in vitro characterization of floating sustained-release drug delivery systems of polyphenols. Drug Deliv. 2013;20(3-4):180–189. https://doi.org/10.3109/10717544.2013.801532..
DOI: 10.3109/10717544.2013.801532
El Nabarawi M.A., Teaima M.H., Abd El-Monem R.A., El Nabarawy N.A., Gaber D.A. Formulation, release characteristics, and bioavailability study of gastroretentive floating matrix tablet and floating raft system of Mebeverine HCl. Drug Des Devel Ther. 2017;11:1081–1093. https://doi.org/10.2147/DDDT.S131936..
DOI: 10.2147/DDDT.S131936
Chassagne P., Ducrotte P., Garnier P., Mathiex-Fortunet H. Tolerance and Long-Term Efficacy of Polyethylene Glycol 4000 (Forlax®) Compared to Lactulose in Elderly Patients with Chronic Constipation. J Nutr Health Aging. 2017;21(4):429–439. https://doi.org/10.1007/s12603-016-0762-6..
DOI: 10.1007/s12603-016-0762-6
Evans P.R., Bak Y.T., Kellow J.E. Mebeverine alters small bowel motility in irritable bowel syndrome. Aliment Pharmacol Ther. 1996;10(5):787–793. https://doi.org/10.1046/j.1365-2036.1996.61203000.x..
DOI: 10.1046/j.1365-2036.1996.61203000.x
Van Outryve M., Mayeur S., Meeus M.A., Rosillon D., Hendrickx B., Ceuppens M. A double-blind crossover comparison study of the safety and efficacy of mebeverine with mebeverine sustained release in the treatment of irritable bowel syndrome. J Clin Pharm Ther. 1995;20(5):277–282. https://doi.org/10.1111/j.1365-2710.1995.tb00663.x..
DOI: 10.1111/j.1365-2710.1995.tb00663.x
Lu C.L., Chen C.Y., Chang F.Y., Chang S.S., Kang L.J., Lu R.H., Lee S.D. Effect of a calcium channel blocker and antispasmodic in diarrhoea-predominant irritable bowel syndrome. J Gastroenterol Hepatol. 2000;15(8):925–930. https://doi.org/10.1046/j.1440-1746.2000.02230.x..
DOI: 10.1046/j.1440-1746.2000.02230.x
Lee K.J., Kim N.Y., Kwon J.K., Huh K.C., Lee O.Y., Lee J.S. et al. Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverine. Neurogastroenterol Motil. 2011;23(12):1098–1104. https://doi.org/10.1111/j.1365-2982.2011.01771.x..
DOI: 10.1111/j.1365-2982.2011.01771.x
Hou X., Chen S., Zhang Y., Sha W., Yu X., Elsawah H. et al. Quality of life in patients with Irritable Bowel Syndrome (IBS), assessed using the IBSQuality of Life (IBS-QOL) measure after 4 and 8 weeks of treatment with mebeverine hydrochloride or pinaverium bromide: results of an international prospective observational cohort study in Poland, Egypt, Mexico and China. Clin Drug Investig. 2014;34(11):783–793. https://doi.org/10.1007/s40261-014-0233-y..
DOI: 10.1007/s40261-014-0233-y
Kennedy T., Jones R., Darnley S., Seed P., Wessely S., Chalder T. Cognitive behaviour therapy in addition to antispasmodic treatment for irritable bowel syndrome in primary care: randomised controlled trial. BMJ. 2005;331(7514):435. https://doi.org/10.1136/bmj.38545.505764.06..
DOI: 10.1136/bmj.38545.505764.06
Daniluk J., Malecka-Wojciesko E., Skrzydlo-Radomanska B., Rydzewska G. The Efficacy of Mebeverine in the Treatment of Irritable Bowel Syndrome-A Systematic Review. J Clin Med. 2022;11(4):1044. https://doi.org/10.3390/jcm11041044..
DOI: 10.3390/jcm11041044